Literature DB >> 12534554

Th1/Th2 profile in peripheral blood in atopic cough and atopic asthma.

T Shirai1, K Suzuki, N Inui, T Suda, K Chida, H Nakamura.   

Abstract

BACKGROUND: Eosinophilic tracheobronchitis with cough hypersensitivity, abbreviated as atopic cough, is an important cause of chronic cough. The reason for the absence of airway hyper-responsiveness is unknown, differing from asthma, a Th2 cytokine-mediated disorder.
OBJECTIVE: To compare the type 1 helper T cell (Th1)/Th2 balance in the peripheral blood from subjects with atopic cough and atopic asthma, we assessed the intracellular cytokine production at the single-cell level.
METHODS: Thirty-six subjects (10 patients with atopic cough, 18 with atopic asthma, and eight control subjects) were included. Intracellular IL-4 and IFN-gamma were detected in CD4+ T cells by flow cytometry.
RESULTS: A significantly lower ratio of IFN-gamma-/IL-4-producing CD4+ T cells after phorbol 12-myristate acetate/ionomycin stimulation was found in patients with atopic cough and atopic asthma compared with normal subjects. In comparison between atopic patients, the ratio of IFN-gamma-/IL-4-producing cells was significantly higher in atopic cough than in atopic asthma. However, the proportion of IL-4-producing CD4+ T cells was significantly higher in patients with atopic asthma than in normal control subjects and no significant difference was detected between patients with atopic cough and normal subjects. No significant difference in the proportion of IFN-gamma-producing cells was found between the subjects. Overall, the total IgE levels were positively correlated to the IL-4-producing cells and inversely correlated to the ratio of IFN-gamma-/IL-4-producing cells.
CONCLUSION: These results show the lower degree of Th2 cytokine predominance in atopic cough compared with atopic asthma and suggest the relation between the Th1/Th2 balance and atopic status.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534554     DOI: 10.1046/j.1365-2222.2003.01578.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  7 in total

1.  Interleukin-16 aggravates ovalbumin-induced allergic inflammation by enhancing Th2 and Th17 cytokine production in a mouse model.

Authors:  Chunxia Li; Jun Dai; Guanjun Dong; Qun Ma; Zhihua Li; Hui Zhang; Fenglian Yan; Junfeng Zhang; Bo Wang; Hui Shi; Yuzhen Zhu; Xiaoying Yao; Chuanping Si; Huabao Xiong
Journal:  Immunology       Date:  2019-07       Impact factor: 7.397

2.  Treatment of atopic cough caused by Basidiomycetes antigen with low-dose itraconazol.

Authors:  Haruhiko Ogawa; Masaki Fujimura; Yohei Tofuku
Journal:  Lung       Date:  2004       Impact factor: 2.584

3.  Oral administration of Faecalibacterium prausnitzii and Akkermansia muciniphila strains from humans improves atopic dermatitis symptoms in DNCB induced NC/Nga mice.

Authors:  Yoonmi Lee; Hye Rim Byeon; Seo-Yul Jang; Moon-Gi Hong; Dohak Kim; Dokyung Lee; Joo-Hyun Shin; Yesol Kim; Seung-Goo Kang; Jae-Gu Seo
Journal:  Sci Rep       Date:  2022-05-05       Impact factor: 4.996

4.  Phosphoinositide-dependent kinase 1 targets protein kinase A in a pathway that regulates interleukin 4.

Authors:  Ajay Nirula; Mary Ho; Hyewon Phee; Jeroen Roose; Arthur Weiss
Journal:  J Exp Med       Date:  2006-06-19       Impact factor: 14.307

5.  Delayed asthmatic response to allergen challenge and cytokines released by nonspecifically stimulated blood cells.

Authors:  Zdenek Pelikan
Journal:  ISRN Inflamm       Date:  2013-02-13

6.  Loki zupa (Luooukezupa) decoction reduced airway inflammation in an OVA-induced asthma mouse model.

Authors:  Ying Wei; Muhammadjan Abduwaki; Mihui Li; Qingli Luo; Jing Sun; Yubao Lv; Mammat Nurahmat; Jingcheng Dong
Journal:  Chin Med       Date:  2016-04-29       Impact factor: 5.455

7.  Detection of IL-9 producing T cells in the PBMCs of allergic asthmatic patients.

Authors:  Lei Jia; Ying Wang; Jiangping Li; Sha Li; Yannan Zhang; Juan Shen; Weiping Tan; Changyou Wu
Journal:  BMC Immunol       Date:  2017-07-19       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.